Heron Therapeutics | HRTX - 营业费用

金融业

USD 0.27

USD 252.26M

现金及等价物

USD 20.72M

USD 11.12M

USD 229.85M

USD 92.15M

USD 149.65M

股息收益率

0

USD 38K

USD -3.88M

126

EPS每股收益

USD -0.02

股本和储备

USD 6.91M

USD 29.47M

债务利息支出

USD 600K

USD 433K

USD 140.64M

USD 44.9M

USD -2.95M

USD 40.55M

USD 38K

普通股股本

USD 188.31M

USD -2.95M

USD 40.59M

销售和管理费用

USD 23.74M

USD 54.57M

贸易债权人

USD 11.64M

应收帐款人

USD 89.59M

	营业费用	更改		日
ALKERMES	USD 1.86B		56.17M	2026-09
Alnylam Pharmaceuticals	USD 1.11B		52.78M	2026-09
Amarin	USD 51.48M		113K	2025-12
ANI Pharmaceuticals	USD 637.11M		39.9M	2026-09
Anika Therapeutics	USD 137.28M		3.38M	2026-06
Arrowhead Research	USD 245.35M		30.35M	2026-06
Eisai	JPY 209.6B		6.14B	2026-06
Emergent BioSolutions	USD 555.9M		242.7M	2023-06
GlaxoSmithKline	GBP 6.03B		227M	2026-09
Heron Therapeutics	USD 40.55M		1.46M	2025-12
Insmed	USD 606.26M		79.46M	2026-09
Ligand Pharmaceuticals	USD 94.5M		39.4M	2026-09
Merck	USD 10.75B		5.02B	2026-09
Nektar Therapeutics	USD 49.12M		8.22M	2026-03
Neurocrine Biosciences	USD 779.7M		40.6M	2026-09
Omeros	USD 59.16M		20.13M	2024-06
Pacira	USD 1.18B		995.96M	2026-09
Regeneron Pharmaceuticals	USD 33.5B		1.79B	2026-09
Roche Holding	CHF 18.9B		2.12B	2026-06
Sangamo BioSciences	USD 33.87M		12.89M	2024-06
Ultragenyx Pharmaceutical	USD 283M		6M	2026-09
Veracyte	USD 133.73M		7.37M	2026-09
Vertex Pharmaceuticals	USD 2.18B		118.2M	2026-09